Showing Articles
Lindsay Bealor Greenleaf weighs in on 2018 drug policy
Lindsay Bealor Greenleaf’s guest column in Drug Store News reviews drug pricing reforms of 2018 and expectations for 2019.
Read more
MEDCAC Q&A with Louis Jacques, ADVI Chief Medical Officer
On May 16, the Centers for Medicare and Medicaid Services (CMS) released a tracking sheet for a National Coverage Analysis (NCA) for Chimeric Antigen Receptor (CAR) T-cell therapies. CMS simultaneously announced an August 22 public meeting of its Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) advisory panel meeting on CAR-T therapies.
Read more
Are We at the Tipping Point for Personalized Medicine IVDS?
ADVI senior leaders discuss challenges and opportunities for molecular diagnostic tests in the context of Medicare’s recent national coverage determination and other developments.
Read more
Op-Ed: Hospitals, Middlemen Inflating Healthcare Costs
To start, the NHE data shows spending on hospital care continues to grow faster than overall healthcare spending. This is especially notable considering hospitals enjoy perks that other stakeholders do not have access to, like $25 billion in annual tax breaks, and large prescription drug discounts ($16 billion in 2016 alone). The “340B Drug Discount Program” was enacted by Congress to help uninsured patients by providing eligible hospitals with steep discounts on prescription drugs. But the statute neglected to explicitly require that these discounts be passed on to patients, which has allowed 340B hospitals to profit from patients buying medicines at full cost even though the hospitals received enormous discounts for the drugs.
Read more